Article and Video CATEGORIES

Cancer Journey

Search By

Can Patients Benefit from Broad vs. Focal Genetic Testing?
Thu, 12/10/2015 - 06:00
GRACE Videos and Articles



Drs. Ben Solomon, Leora Horn, & Jack West evaluate the merits of broad genetic testing with a "next generation sequencing" platform compared to selective, limited testing for the most proven driver mutations in patients with advanced NSCLC.


Download Transcript

[ratingwidget post_id=0]

Please feel free to offer comments and raise questions in our Discussion Forums.



Dr. West:  One of the bigger questions in the whole management of lung cancer is now whether and how often to do broad genomic testing, or really focal testing for a few clearly actionable mutations like EGFR, ALK rearrangement, ROS1, perhaps others that may emerge. What’s your approach — where do you think that your rank and file community oncologist should be, in terms of using broad genomic testing to find, not only the more common ones, but the rarer ones? Do we have enough rare mutations now to widen the scope of our looking, or are there barriers, whether it’s the turnaround time, or others interpreting the results of various rare rabbit holes to go down, that it make it not ready for prime time? Leora, what do you think?

Dr. Horn:  A lot of academic sites are doing it because we have clinical trials. If we’re talking about practical, you know, what day-to-day, I think that it’s important, at minimum, to do EGFR, ALK, ROS, RET, and even BRAF, because there’s been some promising data. If you can get that all done, and maybe it’s through multiplex testing, or next generation sequencing — the problem is, sometimes these test results come back and you get mutations, you don’t know what to do with them, or there’s nothing available for those patients. So, for a day-to-day, practical, we should do those minimal, actionable mutations. I think it’s always nice to know the additional information, but I don’t think it’s essential in making treatment decisions.

Dr. West:  Ben, what do you think?

Dr. Solomon:  So, I agree — I think what’s essential is that a patient gets the best available treatment. Now, the best available treatment will vary from place to place, and country to country, but currently, in most places around the world, EGFR inhibitors and ALK inhibitors are available, and guidelines from professional societies, such as the College of Pathologists, and ASCO, and IASLC, recommend at a minimum testing for EGFR and ALK, and I think that’s a minimum. Now, I think there’s a good case for adding things like ROS1, because of availability of crizotinib, and with the availability of trials at different molecular targets, I think there is a good reason, in most academic centers at least, to expand the panel to include a larger number of actionable mutations, and I think the eventual place that we’ll get to is where all of these tests get done in one test, and we get a report analogous to a Foundation Medicine report that sums up the actionable mutation.

Dr. West:  Yeah, I think once get beyond three of four, it starts to tip the scale toward just get everything at once. I mean, if we’re moving to a time when HER2 mutations, and MET over amplification, as well as, as you said, BRAF, and others, I mean, there’s RET — the list is getting long enough, and it seems that we’re adding maybe one or two every year or so, that hopefully it will be worth doing a broad panel approach for the majority of patients. But, as you say, it depends on where you are and what your access is.

Next Previous link

Previous PostNext Post

Related Content

Forum Discussions

Hi JW and welcome to Grace. I'm sorry you're going through this but hopefully and probably this isn't cancer. There is so much going on anatomically in that area that the...

Hi and welcome to Grace. I'm so sorry about your mom's situation, it's very complicated and not at all reasonable for us to comment on all that is being taken into...

Hi Scruboak, I will ask Dr. West to comment, it may be tomorrow. He's an expert in the field and will have thoughtful input. The fact that it was caught and...

I asked Dr. West and he said that this is a question he can't answer, we don't have studies that give details that specific. He said to his knowledge, that this...

Thank you so much, Janine. It helps me to just chill overall.

It's surprising how a little piece of intel can make everything else in life easier.

Hi Scrappy,


Below I've pasted my comment from facebook. Google is a double-edged sword, you can find anything but without some context, it can be tough to digest. We get...

Recent Comments

Hi JW and welcome to Grace. …
By JanineT Forum … on Mon, 05/16/2022 - 10:52
All's good
By JanineT Forum … on Sat, 05/14/2022 - 15:10
Can Pancoast affect both sides of the body?
By JanineT Forum … on Wed, 05/11/2022 - 19:49
Hi and welcome to Grace. I…
By JanineT Forum … on Sun, 04/24/2022 - 08:41